Cubist Systematic Strategies’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Cubist Systematic Strategies’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-167	Closed	-$1K	–	1991
2016 Q2	$1K	Buy	+167	New	+$1.13K	﹤0.01%	1692
2016 Q1	–	Sell	-2,808	Closed	-$37K	–	1968
2015 Q4	$37K	Buy	+2,808	New	+$48.4K	﹤0.01%	1635
2015 Q3	–	Sell	-2,021	Closed	-$45K	–	2136
2015 Q2	$45K	Buy	+2,021	New	+$32K	﹤0.01%	1714
2014 Q3	–	Sell	-2,040	Closed	-$40K	–	1963
2014 Q2	$40K	Buy	+2,040	New	+$36K	﹤0.01%	1422

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cubist Systematic Strategies's CASC Position: Q3 2016 in Review

Cubist Systematic Strategies sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2016, closing a stake of 167 shares — an estimated $1K sold.

Cubist Systematic Strategies first reported a position in CASC in Q2 2014 and held it in 4 quarters. The position peaked at $45K in Q2 2015. 76 funds tracked by Wall St. Rank hold CASC as of Q3 2016.

Cubist Systematic Strategies reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Cubist Systematic Strategies sold 167 Cascadian Therapeutics, Inc. shares in Q3 2016, an estimated $1K.
Cubist Systematic Strategies first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 4 quarters.
Cubist Systematic Strategies's Cascadian Therapeutics, Inc. position peaked at $45K in Q2 2015.
76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2016.

Based on Cubist Systematic Strategies's 13F filing for Q3 2016, filed 14 Nov 2016.